Abstract
Well-differentiated prostatic cancer cells, like normal prostatic cells, remain for a time, androgen-dependent. Oestrogens in sufficient dosage reduce circulating androgens, and this has been the rationale for conventional oestrogen therapy. At least 3 mg. daily of Stilboestrol, in divided doses, are needed to suppress plasma testosterone levels throughout 24 hours (1,2), but clinically 1 mg. per day is as effective in controlling the disease (3). This therapeutic evidence for an additional direct action of oestrogens upon the prostate is supported by the classical animal experiments of Huggins and Clark in 1940 (4) and by the tissue culture studies of Earnsworth (5).
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsReferences
M.R.G. Robinson and B.G. Thomas, Effect of Hormone Therapy and Plasma Testosterone Levels in Prostatic Cancer, B.M.J. 4:391 (1971).
R.J. Shearer, W.F. Hendry, I.F. Sommeryille and J.D. Fergusson, Plasma Testosterone: An Accurate Monitor of Hormone Treatment in Prostatic Cancer, Brit. J. Urol. 45:668 (1973).
D.P. Byar, The Veterans Administrators Co-operative Urological Group’s Studies of Cancer of the Prostate: A Preliminary Report, Cancer 32:1126 (1973).
C. Huggins and P.J. Clark, The Effects of Castration and Estrogen Injections on the Normal and Hyperplastic Prostate Gland of Dogs, J. Exp. Med. 72:747 (1941).
W.E. Farnsworth, The Normal Prostate and Its Endocrine Control, in “The Third Tenovus Workshop — Some Aspects of the Aetiology and Biochemistry of Prostatic Cancer”, K. Griffith and C.G. Pierrpoint (eds), Alpha Omega Ltd., Cardiff (1970) p. 3.
E.F. Hawkins et al, Steroid Receptors in the Human Prostate, Steroids, 26:458 (1975).
J.R. Murphy, R.C. Emmott, L.L. Hicks and P.C. Walsh, Estrogen Receptors in the Human Prostate, Seminal Vesicle, Testes and Genital Skin: A Marker for Estrogen — Responsive Tissues? J. Clin. Endocrinol. and Metab. 50:938 (1980).
T.T. Kiang and B.J. Kennedy, Tamoxifen (Antioestrogen) Therapy in Advanced Breast Cancer, Ann. Intern. Med. 87:687 (1977).
S. Legha and F.M. Muggia, Antiestrogens in the Treatment of Cancer, Ann. Intern. Med. 84:751 (1976).
R.C. Heel, R.C. Brogden, T.M. Speight and G.S. Avery, Tamoxifen; A Review of its Pharmacological Properties and Their Therapeutic Use in the Treatment of Breast Cancer, Drugs. 16:1 (1968).
M.M. Ip, R.J. Milholland and F. Rosen, Functionality of Estrogen Receptor and Tamoxifen Treatment of R3327 Dunning Rat Prostate Adenocarcinoma, Cancer Res. 40:2188 (1980).
F. Comhaire, Hormone Effect of an Antioestrogen, Tamoxifen, in Normal and Oligospermic Men, Fertility and Sterility, 29:320 (1978).
F.K. Habib, G. Rafat, M.R.G. Robinson and S.R. Stitch, Effects of Tamoxifen on the Binding and Metabolism of Testosterone by Human Prostatic Tissue and Plasma in Vitro, J. Endocrinol. 83:369 (1979).
J.L. Williams, Personal Communication (1980).
L.R. Morgan, L.E. Posey and J. Lanasa, Therapeutic Use of Nolvadex (Tamoxifen ICI 46, 4741) in Advanced Prostatic Cancer, Proc. of 12. Int. Cancer Congress, Beunos Aires, 5–11 October 1978, W51 page 111, Abstract 17.
J.H. Glick, A. Wein, K. Padavic, W. Negendamk, D. Harris and H. Brodovsky, Tamoxifen in Refractory Metastatic Carcinoma of the Prostate, Cancer Treat. Rep. 64:813 (1980).
W.B. Pratt and R.W. Ruddon, “The Anticancer Drugs, Oxford University Press, (1979) p. 212.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1983 Springer Science+Business Media New York
About this chapter
Cite this chapter
Robinson, M.R.G. (1983). Nolvadex (Tamoxifen) an Antioestrogen of Potential Use in the Management of Carcinoma of the Prostate. In: Pavone-Macaluso, M., Smith, P.H. (eds) Cancer of the Prostate and Kidney. NATO Advanced Science Institutes Series, vol 53. Springer, Boston, MA. https://doi.org/10.1007/978-1-4684-4349-3_42
Download citation
DOI: https://doi.org/10.1007/978-1-4684-4349-3_42
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4684-4351-6
Online ISBN: 978-1-4684-4349-3
eBook Packages: Springer Book Archive